SQZ - SQZ STOCK NEWS

SQZ Biotechnologies (NYSE: SQZ) showcased preclinical data at the 2021 International Society for Stem Cell Research meeting, revealing that its Cell Squeeze® technology can generate neurons from induced human pluripotent stem cells (iPSCs) via single mRNA delivery. Key findings include rapid neuronal differentiation within 24 hours, a 10,000-fold increase in target gene expression, and the ability to co-deliver multiple mRNAs without disrupting iPSC functions. This technology promises significant advancements in regenerative medicine and offers a scalable approach to cell reprogramming.

SQZ Biotechnologies (NYSE: SQZ) has presented preclinical results from its Tolerizing Antigen Carrier (TAC) program, demonstrating the potential of SQZ TACs in inducing immune tolerance for autoimmune diseases like Type 1 diabetes (T1D). SQZ TACs showed significant results, including a 65-day delay in disease onset and substantial reduction of pathogenic T cells. The engineered TACs increased regulatory T cells and exhibited bystander suppression abilities. This innovative approach could lead to promising therapeutics targeting T1D.

SQZ Biotechnologies presented promising initial results from its Phase 1 trial of SQZ-PBMC-HPV, aimed at treating HPV16+ tumors. The investigational therapy demonstrated safety and tolerability across all tested doses, with no dose-limiting toxicities reported. Notably, four patients achieved stable disease despite advanced cancer status. The trial's manufacturing process is efficient, producing doses within 24 hours. This research supports future combination trials with immune checkpoint inhibitors. The findings, shared at the ASCO meeting, underscore the potential of SQZ-PBMC-HPV in advancing cell therapies.

SQZ Biotechnologies (NYSE:SQZ), a leader in cell therapy, will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. CEO Armon Sharei will provide a corporate overview on June 2 at 3:00 pm EDT through a virtual webcast. The webcast will be accessible for 30 days post-presentation, allowing stakeholders to gain insights into the company's innovative cell therapy solutions for cancer and other serious diseases.

SQZ Biotechnologies (NYSE: SQZ) will present data from its Phase 1 clinical trial of SQZ-PBMC-HPV-101 for HPV-positive tumors at the 2021 ASCO Annual Meeting. Early results show the therapy is well-tolerated at all doses with signals of immune activity. The trial includes three dose-escalating cohorts, with ongoing enrollment for the highest dose. Manufacturing of the therapy has been efficient, allowing rapid patient treatment. The next phase will explore combining SQZ-PBMC-HPV-101 with immune checkpoint inhibitors.

SQZ Biotechnologies (NYSE: SQZ) announced its Q1 2021 financial results, reporting revenue of $5.5 million, down from $6.4 million in Q1 2020. R&D expenses rose to $14.7 million from $11.9 million, driven by the SQZ-AAC-HPV IND program and other preclinical projects. The net loss increased to $15.4 million compared to $10.6 million the previous year. Cash and equivalents were $204.9 million, sufficient to fund operations through mid-2023. The company continues to advance its cell therapy pipeline, notably the SQZ APC Phase 1 trial and IND clearance for the SQZ AAC program.

SQZ Biotechnologies (NYSE:SQZ) will participate in the BofA Securities 2021 Virtual Health Care Conference from May 11-13, 2021. On May 12 at 8:00 AM EDT, CEO Armon Sharei, PhD, will provide a corporate overview via a webcast, which will be accessible for 90 days post-presentation. SQZ Biotechnologies specializes in developing innovative cell therapies for serious conditions, aiming to redefine treatment paradigms with rapid production timelines.

SQZ Biotechnologies (NYSE: SQZ) announced its presentation of new data on its cGMP cell therapy manufacturing program at the ASGCT Virtual Annual Meeting from May 11-14. The company demonstrated that its Cell Squeeze® Technology can process 10 billion cells per minute with over 90% viability. SQZ-PBMC-HPV, their first investigational drug, is in Phase 1 clinical trials for HPV+ tumors. The technology shows advantages over traditional electroporation methods, highlighting its potential for engineering viable T cells for various therapies.

SQZ Biotechnologies (NYSE: SQZ) presented promising preclinical data on its next-generation SQZ™ APCs and eAPCs at the AACR 2021 Annual Meeting. These enhanced cell therapies aim to amplify immune responses by integrating multiple functionalities within a single treatment. Key findings showed significant increases in antigen-specific CD8 T cell activation, potentially broadening the patient population for HPV+ cancers. The innovative approach could revolutionize cancer treatment, illustrating the flexibility and efficacy of SQZ's Cell Squeeze® technology.